Faron Pharmaceuticals Ltd   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Turku Finland (2006)

Organization Overview

First Clinical Trial
2009
NCT00789685
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Faron Pharmaceuticals Ltd

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 3)

Lung Injury (Phase 2)

Multiple Organ Failure (Phase 2)

Respiratory Distress Syndrome (Phase 3)

Respiratory Distress Syndrome, Newborn (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 8